Search - tctmd.com

Displaying 1 - 20 of 934

Sort: Relevancy | Date

News Daily News

Genomics, Lipids, Inflammation at Midlife Predict Future CAD

Caitlin E. Cox

March 25, 2026

News Daily News

Improved Lipids With Gastric Bypass Linked to Surgery Itself, Not Weight Loss

Michael O'Riordan

July 23, 2024

News Daily News

Genetic Study Hints at Role of Lipids in AAA Risk

Michael O'Riordan

November 30, 2017

News Conference News AHA 2025

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

Michael O'Riordan

November 10, 2025

Presentation

High-Dose Atorvastatin on the Pharmacodynamic Effects of Double-Dose Clopidogrel in Patients Undergoing PCI

Presenter: 147520|Massimo Leoncini

February 24, 2013

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

Presentation TCT 2012

A Prospective, Randomized Trial of Rosuvastatin Loading Prior to PCI

Presenter: Josef Veselka

October 22, 2012

News Daily News

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Michael O'Riordan

January 26, 2016

News Daily News

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Michael O'Riordan

January 26, 2016

News Daily News

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Michael O'Riordan

January 26, 2016

Presentation TCT 2013

Impact of Anti-anginal Therapy and Rate Pressure Product Control on the Need for Repeat Revascularization Post-PCI

Presenter: Subhash Banerjee, Rick Weideman, Bertis Little, Mark Weideman, Jennifer Gunter, Kevin Kelly, Emmanouil Brilakis

January 31, 2013

Presentation

Impact of a High Loading Dose of Atorvastatin on Contrast-Induced Acute Kidney Injury

Presenter: C. Quintavalle

November 15, 2012

News Industry News

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

January 21, 2016

Presentation TCT 2013

Nicorandil Prevents Microvascular Dysfunction Resulting from Percutaneous Coronary Intervention in Patients with Stable Angina Pectoris

Presenter: Atsushi Hirohata, Eiki Hirose, Yuhei Kobayashi, Minako Ohara, Tohru Ohe, Fumihiko Sano, Hiroya Takafuji, Hiroyuki Takinami, Keizo Yamamoto, Ryo Yoshioka

January 31, 2013

News Conference News ESC 2016

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Michael O'Riordan

August 30, 2016

News Conference News ESC 2016

Long-term Exposure to Lower LDL Cholesterol, Blood Pressure Has Potential to Dramatically Cut CV Risk

Todd Neale

August 29, 2016

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

News Daily News

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

Yael L. Maxwell

August 29, 2016

News Daily News

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

Yael L. Maxwell

August 29, 2016

News Daily News

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Yael L. Maxwell

August 29, 2016

Advertisement

Genomics, Lipids, Inflammation at Midlife Predict Future CAD

Improved Lipids With Gastric Bypass Linked to Surgery Itself, Not Weight Loss

Genetic Study Hints at Role of Lipids in AAA Risk

Oral PCSK9 Inhibitor Enlicitide Cuts LDL Cholesterol: CORALreef Lipids

High-Dose Atorvastatin on the Pharmacodynamic Effects of Double-Dose Clopidogrel in Patients Undergoing PCI

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

A Prospective, Randomized Trial of Rosuvastatin Loading Prior to PCI

在他汀类药物治疗基础上添加依泽替米贝可以降低首次和后续心血管事件的风险：IMPROVE-IT 分析

Análisis del IMPROVE-IT: La Incorporación de Ezetimibe al Tratamiento con Estatinas Reduce el Riesgo de Sufrir Primeros y Subsiguientes Episodios CV

Adding Ezetimibe to Statin Therapy Reduces Risk of First and Subsequent CV Events: IMPROVE-IT Analysis

Impact of Anti-anginal Therapy and Rate Pressure Product Control on the Need for Repeat Revascularization Post-PCI

Impact of a High Loading Dose of Atorvastatin on Contrast-Induced Acute Kidney Injury

Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol

Nicorandil Prevents Microvascular Dysfunction Resulting from Percutaneous Coronary Intervention in Patients with Stable Angina Pectoris

Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER

Long-term Exposure to Lower LDL Cholesterol, Blood Pressure Has Potential to Dramatically Cut CV Risk

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

更高效、更廉价：成本效益分析称 PCSK9 价格需降低三分之二

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

More Bang, Less Buck: Cost-Effectiveness Analysis Says Price of PCSK9 Inhibitors Needs to Drop by Two-Thirds

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content